DANVERS, Mass--(BUSINESS WIRE)--Mar. 14, 2019--
The hemodynamic support of Abiomed’s
(NASDAQ: ABMD) Impella
heart pump platform for high-risk PCI and treatment of cardiogenic
shock will be highlighted in more than 30 presentations and posters at
College of Cardiology’s (ACC) 68th Annual Scientific SessionMarch
16-18, in New Orleans.
Impella is the only FDA approved, safe and effective heart pump for
high-risk PCI, cardiogenic shock, and right ventricular failure, and has
supported more than 100,000 patients in the United States, Germany and
Japan. Abiomed remains committed to advancing the field of heart
recovery through clinical
research and support, education, and innovation. Impella will be
featured at ACC with:
- Presentations of Clinical Data
- Interactive Learning at Abiomed’s Booth
#129 will feature clinical data and hands-on learning with the Impella
platform including Impella
with SmartAssist and Impella
Connect, which provide advanced
technology and 24x7 clinical support services to improve patient
outcomes. Abiomed’s pipeline products including Impella 5.5™, Impella
ECP™, Impella BTR™, and expandable sheath1 will be
included. Abiomed’s simulation training tool will allow attendees to
experience Impella CPheart pump insertion, placement, and
- Potential Live High-Risk PCI Case Using the Impella Heart Pump
PCI with Impella improves quality of life and reduces post-discharge
major adverse cardiovascular and cerebrovascular events (MACCE) by 47%
at 90 days2. Abiomed anticipates the potential broadcast of
an elective live Protected PCI case from Beth Israel Deaconess Medical
Center utilizing Impella during the conference.
For more information about Abiomed and heart recovery, visit www.abiomed.com.
1. The Impella 5.5™ heart pump is not approved for use or sale in the
U.S. Impella ECP™ and Impella BTR™ heart pumps, and the expandable
sheath are in development and are not approved for use or sale.
O’Neill WW et al. Circulation. PROTECT II Randomized Controlled
Trial. 2012 Oct 2:126(14):1717-27.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5 and Impella CP devices are FDA approved to treat certain
advanced heart failure patients undergoing elective and urgent
percutaneous coronary interventions (PCI) such as stenting or balloon
angioplasty, to re-open blocked coronary arteries. The Impella 2.5®,
Impella CP®, Impella CP® with SmartAssist, Impella
5.0® and Impella LD® are FDA approved heart pumps
used to treat heart attack or cardiomyopathy patients in cardiogenic
shock, and have the unique ability to enable native heart recovery,
allowing patients to return home with their own heart. To learn more
about the Impella platform of heart pumps, including their approved
indications and important safety and risk information associated with
the use of the devices, please visit: www.protectedpci.com.
The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0, Impella
LD, Impella CP, Impella RP, Impella Connect, and Recovering hearts.
Saving lives. are registered trademarks of ABIOMED, Inc. in the U.S. and
in certain foreign countries.
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of
medical devices that provide circulatory support. Our products are
designed to enable the heart to rest by improving blood flow and/or
performing the pumping of the heart. For additional information, please
This release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the
Company's progress toward commercial growth, and future opportunities
and expected regulatory approvals. The Company's actual results may
differ materially from those anticipated in these forward-looking
statements based upon a number of factors, including uncertainties
associated with development, testing and related regulatory approvals,
including the potential for future losses, complex manufacturing, high
quality requirements, dependence on limited sources of supply,
competition, technological change, government regulation, litigation
matters, future capital needs and uncertainty of additional financing,
and other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any forward-looking
statements, which speak only as of the date of this release. The Company
undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to
reflect events or circumstances that occur after the date of this
release or to reflect the occurrence of unanticipated events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190314005241/en/
Source: Abiomed, Inc.
Director, Communications and Public Relations
Ingrid Goldberg Ward
Director, Investor Relations